Discover open access scientific publications

Search, annotate, share and cite publications

Publications in Pulmonary

P3.09-02 Utilization of Laboratory Developed Tests for PD-L1 Evaluation Is Dependent on Tumor Type

Journal of Thoracic Oncology

English

P3.13-17 a Retrospective Study: Central Nervous System Response to Osimertinib in Patients With Advanced NSCLC

Journal of Thoracic Oncology

English

P3.17-12 Phase II Trial of Atezolizumab Before and After Chemoradiation for Unresectable Stage III NSCLC (AFT-16): Trial in Progress

Journal of Thoracic Oncology

English

MA06.10 Germline Mutation in ATM Affect Lung Cancer Risk With High Effect

Journal of Thoracic Oncology

English

P074 Study on the Mechanisms of VASH2/TGF-β/VEGF-D in Promoting the Lymph Node Metastasis of Lung Squamous Cell Carcinoma

Journal of Thoracic Oncology

English

P1.01-57 the Role of EGFR Mutation as a Prognostic Factor in Survival After Diagnosis of Brain Metastasis in NSCLC: A Systematic Review and Meta-Analysis

Journal of Thoracic Oncology

English

P1.09-27 Clear Cell Adenocarcinoma Subtype Is an Independent Predictor of Better Survival in Patients With Lung Adenocarcinoma

Journal of Thoracic Oncology

English

OA08 Efficacy and Safety of Sintilimab Combined With 1st Line Chemotherapy in Advanced Squamous Cell Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

English

OA13 High-Dose Icotinib in Advanced NSCLC With EGFR 21 L858R Mutation: A Randomized, Open-Label Phase II Study

Journal of Thoracic Oncology

English

MA08.01 Phase 3 Trial of Whole Brain Radiotherapy With Concurrent Erlotinib Versus WBRT Alone for NSCLC With Brain Metastases (ENTER)

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications in Pulmonary

P3.09-02 Utilization of Laboratory Developed Tests for PD-L1 Evaluation Is Dependent on Tumor Type

P3.13-17 a Retrospective Study: Central Nervous System Response to Osimertinib in Patients With Advanced NSCLC

P3.17-12 Phase II Trial of Atezolizumab Before and After Chemoradiation for Unresectable Stage III NSCLC (AFT-16): Trial in Progress

MA06.10 Germline Mutation in ATM Affect Lung Cancer Risk With High Effect

P074 Study on the Mechanisms of VASH2/TGF-β/VEGF-D in Promoting the Lymph Node Metastasis of Lung Squamous Cell Carcinoma

P1.01-57 the Role of EGFR Mutation as a Prognostic Factor in Survival After Diagnosis of Brain Metastasis in NSCLC: A Systematic Review and Meta-Analysis

P1.09-27 Clear Cell Adenocarcinoma Subtype Is an Independent Predictor of Better Survival in Patients With Lung Adenocarcinoma

OA08 Efficacy and Safety of Sintilimab Combined With 1st Line Chemotherapy in Advanced Squamous Cell Non-Small Cell Lung Cancer

OA13 High-Dose Icotinib in Advanced NSCLC With EGFR 21 L858R Mutation: A Randomized, Open-Label Phase II Study

MA08.01 Phase 3 Trial of Whole Brain Radiotherapy With Concurrent Erlotinib Versus WBRT Alone for NSCLC With Brain Metastases (ENTER)